Welcome to our dedicated page for LakeShore Biopharma Co. news (Ticker: LSB), a resource for investors and traders seeking the latest updates and insights on LakeShore Biopharma Co. stock.
LakeShore Biopharma Co., Ltd (LSB), previously known as YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The news flow around LakeShore Biopharma reflects both its scientific and commercial activities and its capital markets and corporate developments.
Company news commonly highlights progress in its vaccine portfolio, particularly the YSJA ae rabies vaccine (Vero cell), which LakeShore Biopharma describes as China 27s first aluminum-free lyophilized rabies vaccine (Vero cell) for post-exposure protection. Updates have included the launch of a novel packaging solution using a liquid drug transfer device designed to support needle-free reconstitution and reduce occupational exposure risks for medical staff, as well as clinical pipeline milestones such as a Phase III trial of a simplified four-dose regimen for the YSJA ae rabies vaccine.
Investors following LSB-related news can also see disclosures on financial performance, financing transactions, and corporate structure. The company has reported fiscal year financial results, including the use of non-GAAP measures like EBITDA and Adjusted EBITDA, and has announced private placement financing involving ordinary shares and warrants. In addition, LakeShore Biopharma has issued multiple press releases regarding a preliminary non-binding proposal, a revised proposal, and a subsequent definitive agreement for a going-private transaction with Oceanpine-affiliated entities.
Another important category of news involves listing status and trading venues. LakeShore Biopharma has reported receiving a Nasdaq delisting determination letter for non-compliance with the minimum bid price requirement, the suspension of trading of its ordinary shares and warrants on The Nasdaq Capital Market, and the expected commencement of trading on the OTC Pink Open Market under new symbols. Readers can use the LSB news page to review these regulatory and corporate updates, alongside operational and clinical announcements, in one place.
LakeShore Biopharma (Nasdaq: LSB) will hold an Extraordinary General Meeting (EGM) on July 25, 2024, following a shareholders' requisition. The requisition, dated June 14, 2024, was issued by shareholders holding at least 10% of the voting shares, including Yi Zhang and several investment firms. The EGM will address key issues such as the reasons for recent director resignations, the establishment of new subsidiaries, and the potential impact of ongoing arbitration proceedings. The meeting will be held virtually via Zoom, and shareholders of record on July 15, 2024, are entitled to vote. Detailed information is available on the company's website and will be included in the Form 6-K filed with the SEC.